

Steve Sisolak
Governor
Richard Whitley, MS
Director



**DEPARTMENT OF
HEALTH AND HUMAN SERVICES**
Division of Health Care Financing and Policy
Helping people. It's who we are and what we do.



Suzanne Bierman, JD, MPH
Administrator

NOTICE OF PUBLIC MEETING – SILVER STATE SCRIPTS BOARD

AGENDA

- Date of Publication:** November 6, 2019
- Date and Time of Meeting:** December 5, 2019 at 1:00 PM
- Name of Organization:** The State of Nevada, Department of Health and Human Services (DHHS), Division of Health Care Financing and Policy (DHCFP)
- Place of Meeting:** Springs Preserve
333 S. Valley View Blvd.
Las Vegas, Nevada 89107
- Please check with staff to verify room location
- There will not be a North Location for this meeting.
- Webinar Registration:** <https://optum.webex.com/optum/onstage/g.php?MTID=e7c8ae9973482e8608d7bf7a18860d260>

OR

www.webex.com, select “Join”, enter Meeting Number 641 988 280, your name and email and then select, “Join”.

A Password should not be necessary, but if asked, enter, “Medicaid1!”

OR

- Audio Only:** (763) 957-6300
Event Number: 641 988 280
Follow the instructions that appear on your screen to join the teleconference. Audio will also be broadcast over the internet (VoIP).

Reasonable efforts will be made to assist and accommodate physically challenged persons desiring to attend the meeting. Please call Tanya Benitez at: (775) 684-3730 or email TBenitez@dncfp.nv.gov in advance, but no later than two working days prior to the meeting, so that arrangements may be conveniently made.

Items may be taken out of order.

Items may be combined for consideration by the public body.

Items may be pulled or removed from the agenda at any time.

Public comment is limited to five minutes per individual, organization or agency, but may be extended at the discretion of the Chairperson.

1:00 PM – 2:00 PM – Closed Executive Session

Pursuant to NRS 422.405(4), as amended by Senate Bill 378 during the 80th Legislative session, the Board intends to hold a closed session for discussions between the DHCFP, OptumRx and the Silver State Scripts Board regarding the methodology and selection of preferred agents on the Nevada Medicaid Preferred Drug List (PDL).

Upon Completion of the Closed Executive Session – 5:00 PM – Public Meeting (Open Session)

AGENDA

- I. Call to Order
- II. Roll Call
- III. Public Comment
- IV. Old Business
 1. For Possible Action: Review and Approve Meeting Minutes from September 26, 2019
- V. New Business
 1. Status Update by the DHCFP
 2. Established Drug Classes Being Reviewed Due to the Release of New Drugs
 - A. Dermatological Agents: Topical Antipsoriatic Agents
 1. Public Comment
 2. Drug Class Review Presentation – OptumRx
 3. For Possible Action: Board Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class

4. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
 5. For Possible Action: Board Discussion and Action
 - a. Approval of drugs for Inclusion on the PDL
- B. Hormones and Hormone Modifiers: Antidiabetic Agents - Incretin Mimetics
1. Public Comment
 2. Drug Class Review Presentation – OptumRx
 3. For Possible Action: Board Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 4. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
 5. For Possible Action: Board Discussion and Action
 - a. Approval of drugs for Inclusion on the PDL
- C. Neurological Agents: Anticonvulsants – Benzodiazepines
1. Public Comment
 2. Drug Class Review Presentation – OptumRx
 3. For Possible Action: Board Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 4. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
 5. For Possible Action: Board Discussion and Action
 - a. Approval of drugs for Inclusion on the PDL
3. Established Drug Classes
- A. Analgesics: Opiate Agonists (Opiate Agonists, Abuse Deterrent Opiate Agonists)
1. Public Comment
 2. Drug Class Review Presentation – OptumRx
 3. For Possible Action: Board Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 4. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
 5. For Possible Action: Board Discussion and Action
 - a. Approval of drugs for Inclusion on the PDL
- B. Monoclonal Antibodies for the treatment of Respiratory Conditions
1. Public Comment
 2. Drug Class Review Presentation – OptumRx

3. For Possible Action: Board Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 4. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
 5. For Possible Action: Board Discussion and Action
 - a. Approval of drugs for Inclusion on the PDL
- C. Neurological Agents: Anti-Migraine Agents-Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonists, Serotonin-Receptor Agonists
1. Public Comment
 2. Drug Class Review Presentation – OptumRx
 3. For Possible Action: Board Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 4. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
 5. For Possible Action: Board Discussion and Action
 - a. Approval of drugs for Inclusion on the PDL
- D. Respiratory Agents: Nasal Antihistamines
1. Public Comment
 2. Drug Class Review Presentation – OptumRx
 3. For Possible Action: Board Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 4. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
 5. For Possible Action: Board Discussion and Action
 - a. Approval of drugs for Inclusion on the PDL
- E. Toxicology Agents: Agents for the Treatment of Substance Abuse
1. Public Comment
 2. Drug Class Review Presentation – OptumRx
 3. For Possible Action: Board Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 4. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
 5. For Possible Action: Board Discussion and Action
 - a. Approval of drugs for Inclusion on the PDL
4. Report by OptumRx on New Drugs to Market, New Generic Drugs to Market, and New Line Extensions

5. Closing Discussion
 - A. Public comments on any subject
 - B. Date and location of the next meeting
 - C. Adjournment

This notice and agenda have been posted at <http://dhcfnv.gov/> and notice.nv.gov/.

Notice of this meeting and draft copies of the changes will be available on or after the date of this notice at the DHCFP Web site <http://dhcfnv.gov/>, Carson City Central office and Las Vegas DHCFP. The agenda posting of this meeting can be viewed at the following locations: Nevada State Library; Carson City Library; Churchill County Library; Las Vegas Library; Douglas County Library; Elko County Library; Lincoln County Library; Lyon County Library; Mineral County Library; Tonopah Public Library; Pershing County Library; Goldfield Public Library; Eureka Branch Library; Lander County Library; Storey County Library; Washoe County Library; and White Pine County Library and may be reviewed during normal business hours.

If requested in writing, a draft copy of the changes will be mailed to you. Requests and/or written comments on the proposed changes may be sent to the DHCFP, 1100 E. William Street, Suite 101, Carson City, NV 89701.

All persons that have requested in writing to receive the Public Hearings agenda have been duly notified by mail or e-mail.